BioAge Labs Inc. Financials
Financial Health Signals
BioAge Labs Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, BioAge Labs Inc. generates $0.72 in operating cash flow (-$51.5M OCF vs -$71.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
BioAge Labs Inc. earns $-33.0 in operating income for every $1 of interest expense (-$78.2M vs $2.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows BioAge Labs Inc. (BIOA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
BioAge Labs Inc.'s EBITDA was -$78.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 61.8% from the prior year.
BioAge Labs Inc. generated -$51.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 38.3% from the prior year.
BioAge Labs Inc. reported -$71.1M in net income in fiscal year 2024. This represents a decrease of 11.4% from the prior year.
BioAge Labs Inc. earned $-6.63 per diluted share (EPS) in fiscal year 2024. This represents an increase of 82.6% from the prior year.
BioAge Labs Inc. held $354.3M in cash against $2.5M in long-term debt as of fiscal year 2024.
BioAge Labs Inc. had 36M shares outstanding in fiscal year 2024. This represents an increase of 2042.5% from the prior year.
BioAge Labs Inc. invested $59.0M in research and development in fiscal year 2024. This represents an increase of 74.2% from the prior year.
BioAge Labs Inc. invested $366K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 120.5% from the prior year.
BIOA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.1M-14.8% | $2.4M+66.2% | $1.5M | $0 | $0 | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $18.5M-6.7% | $19.8M+78.6% | $11.1M-44.5% | $20.0M+91.2% | $10.5M | N/A | $6.5M |
| SG&A Expenses | $6.7M-9.0% | $7.3M+8.1% | $6.8M+43.5% | $4.7M-1.4% | $4.8M | N/A | $3.4M |
| Operating Income | -$23.1M+6.6% | -$24.8M-50.6% | -$16.4M+33.6% | -$24.8M-62.1% | -$15.3M | N/A | -$9.9M |
| Interest Expense | $149K-25.9% | $201K-21.2% | $255K-34.3% | $388K-12.4% | $443K | N/A | $2.4M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$20.2M+6.5% | -$21.6M-66.8% | -$12.9M+44.8% | -$23.4M-72.4% | -$13.6M | N/A | -$14.6M |
| EPS (Diluted) | $-0.56+6.7% | $-0.60-66.7% | $-0.36+94.6% | $-6.70+15.6% | $-7.94 | N/A | $-8.74 |
BIOA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|
| Total Assets | $305.1M-5.3% | $322.1M-6.3% | $343.8M-4.0% | $358.2M | N/A | $25.9M | N/A |
| Current Assets | $290.8M-3.6% | $301.7M-7.1% | $324.8M-9.0% | $357.1M | N/A | $25.3M | N/A |
| Cash & Equivalents | $215.6M-2.2% | $220.3M-14.4% | $257.5M-27.3% | $354.3M | N/A | $21.6M | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $515K-14.6% | $603K+67.0% | $361K | $0 | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $27.6M+0.9% | $27.4M-10.8% | $30.7M-12.6% | $35.1M | N/A | $199.3M | N/A |
| Current Liabilities | $24.5M+7.3% | $22.8M-3.8% | $23.7M-14.5% | $27.8M | N/A | $58.2M | N/A |
| Long-Term Debt | $0 | $0-100.0% | $1.1M-57.8% | $2.5M | N/A | $8.2M | N/A |
| Total Equity | $277.5M-5.9% | $294.8M-5.9% | $313.2M-3.1% | $323.1M+263.9% | -$197.1M-13.7% | -$173.4M-13.2% | -$153.1M |
| Retained Earnings | -$307.5M-7.0% | -$287.3M-8.1% | -$265.7M-5.1% | -$252.8M | N/A | -$181.7M | N/A |
BIOA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.0M+19.7% | -$20.0M-15.0% | -$17.4M-237.9% | -$5.1M+67.4% | -$15.8M-85.6% | -$8.5M | N/A |
| Capital Expenditures | $22K-86.2% | $159K-62.7% | $426K+1538.5% | $26K-25.7% | $35K | $0 | N/A |
| Free Cash Flow | -$16.1M+20.2% | -$20.1M-13.1% | -$17.8M-244.5% | -$5.2M+67.3% | -$15.8M-86.0% | -$8.5M | N/A |
| Investing Cash Flow | $12.8M+182.1% | -$15.6M+79.9% | -$78.0M-299853.8% | -$26K+25.7% | -$35K | $0 | N/A |
| Financing Cash Flow | -$1.5M-2.9% | -$1.5M0.0% | -$1.5M-106.0% | $24.9M+1143.2% | -$2.4M-136.6% | -$1.0M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BIOA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1126.6%-99.6pp | -1027.0%+106.4pp | -1133.4% | N/A | N/A | N/A | N/A |
| Net Margin | -982.0%-88.0pp | -894.0%-3.0pp | -891.0% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -6.6%+0.1pp | -6.7%-2.9pp | -3.8%+3.2pp | -6.9% | N/A | N/A | N/A |
| Current Ratio | 11.87-1.3 | 13.21-0.5 | 13.68+0.8 | 12.86 | N/A | 0.44 | N/A |
| Debt-to-Equity | 0.000.0 | 0.000.0 | 0.000.0 | 0.01 | N/A | -0.05 | N/A |
| FCF Margin | -782.2%+52.3pp | -834.5%+391.5pp | -1226.0% | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is BioAge Labs Inc. profitable?
No, BioAge Labs Inc. (BIOA) reported a net income of -$71.1M in fiscal year 2024.
What is BioAge Labs Inc.'s earnings per share (EPS)?
BioAge Labs Inc. (BIOA) reported diluted earnings per share of $-6.63 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is BioAge Labs Inc.'s EBITDA?
BioAge Labs Inc. (BIOA) had EBITDA of -$78.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioAge Labs Inc. have?
As of fiscal year 2024, BioAge Labs Inc. (BIOA) had $354.3M in cash and equivalents against $2.5M in long-term debt.
What is BioAge Labs Inc.'s free cash flow?
BioAge Labs Inc. (BIOA) generated -$51.9M in free cash flow during fiscal year 2024. This represents a -38.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioAge Labs Inc.'s operating cash flow?
BioAge Labs Inc. (BIOA) generated -$51.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are BioAge Labs Inc.'s total assets?
BioAge Labs Inc. (BIOA) had $358.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are BioAge Labs Inc.'s capital expenditures?
BioAge Labs Inc. (BIOA) invested $366K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does BioAge Labs Inc. spend on research and development?
BioAge Labs Inc. (BIOA) invested $59.0M in research and development during fiscal year 2024.
How many shares does BioAge Labs Inc. have outstanding?
BioAge Labs Inc. (BIOA) had 36M shares outstanding as of fiscal year 2024.
What is BioAge Labs Inc.'s current ratio?
BioAge Labs Inc. (BIOA) had a current ratio of 12.86 as of fiscal year 2024, which is generally considered healthy.
What is BioAge Labs Inc.'s debt-to-equity ratio?
BioAge Labs Inc. (BIOA) had a debt-to-equity ratio of 0.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioAge Labs Inc.'s return on assets (ROA)?
BioAge Labs Inc. (BIOA) had a return on assets of -19.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is BioAge Labs Inc.'s cash runway?
Based on fiscal year 2024 data, BioAge Labs Inc. (BIOA) had $354.3M in cash against an annual operating cash burn of $51.5M. This gives an estimated cash runway of approximately 83 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is BioAge Labs Inc.'s Piotroski F-Score?
BioAge Labs Inc. (BIOA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioAge Labs Inc.'s earnings high quality?
BioAge Labs Inc. (BIOA) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioAge Labs Inc. cover its interest payments?
BioAge Labs Inc. (BIOA) has an interest coverage ratio of -33.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.